Search Results

Results for Clinical trials:

Pierre Azoulay

Pierre Azoulay

International Programs Professor of Management

Department: Professor of Technological Innovation, Entrepreneurship, and Strategic Management

Contact: (617) 258-9766, pazoulay@mit.edu

Expertise: Alliances; Applied microeconomics; Apps; Biopharmaceutical; Biotechnology; Clinical trials; Cloud computing; Cloud storage; Competitive strategy; Corporate strategy and policy; Employee motivation; Hi technology companies; Incentives; Innovation; Innovation management; Innovative thinking; Intellectual property; Intellectual property; Intellectual property law; Intellectual property laws; Labor market policy; Mergers and acquisitions; MOOCs; MOOCs; Non-market strategy; Online education; Outsourcing; Patents; Pharmaceuticals; Product innovation; Research and development; Startups / Start-ups; Strategy; Technological innovation; Technology strategy; Technology transfer; Technology transfer; Twitter; Yelp

Ernst Berndt

Ernst Berndt

Louis E. Seley Professor in Applied Economics

Department: Professor of Applied Economics

Contact: (617) 253-2665, eberndt@mit.edu

Expertise: Affordable Care Act (ACA); Applied economics; Applied microeconomics; Applied probability; Biopharmaceutical; Biotechnology; Cancer; Clinical trials; Data analytics; Drug models; Econometrics; Economics; Education; Game theory; Health management; Healthcare; Healthcare industry; HIV; Industrial organization; Industrial organization; Industrial partnerships; Institutional partnerships; Intellectual property; Intellectual property; Intellectual property law; Market research; Medicaid; Medical decision making; Medical devices; Medicare; Medicine; Microeconomics; Outsourcing; Pharmaceuticals; Pricing; Regulation and policy; Sampling; Statistics; Stochastic modeling

Zen Chu

Zen Chu

Department: Senior Lecturer

Contact: (617) 699-4036, zenven@mit.edu

Expertise: Accelerators; Action learning; Affordable Care Act (ACA); Alibaba; Alibaba; Alliances; Angel investing; Apple; Apps; Asia; Asia Pacific; B-school; Big data; Biopharmaceutical; Biotechnology; Business education; Cancer; China; Clinical trials; Cloud computing; Cloud storage; Competitive strategy; Conflicts of interest; Conflicts of interest; Consumer electronics; Convergence; Corporate social responsibility; Cross-cultural awareness; Crowdfunding; Cultural differences; Cyber security; Developing countries; Developing countries, economics; Digital economy; Digitization; eBusiness; eCommerce; eGovernment; Electronic commerce; Electronic media; Emerging businesses; Emerging markets; Entrepreneurial finance; Entrepreneurial finance; Entrepreneurial management; Entrepreneurship; Executive education; Genetics; Genome; Global entrepreneurship; Global entrepreneurship; Hacking; Healthcare; Healthcare delivery; Healthcare operations management; High technology / Hi-tech; Hospital operations management; Incubators; India; Information technology; Innovation; Innovation management; Innovative thinking; Insurance; Intellectual property; International corporate strategy; International entrepreneurship; Internet applications; Internet security; Internet software; Internet strategy; Internet telephony; iPhone; Knowledge management; Knowledge sharing; Lead users; Lead users; Leadership; Leadership; Medical decision making; Medical devices; Medical devices; Medicare; Medicine; Mergers and acquisitions; MOOCs; Multi-drug models; Nanotechnology; New venture development; New ventures; Obamacare; Open innovation; Open source software; Patents; Pharmaceuticals; Predictive analytics; Private equity; Privatization; Product design; Product development; Product innovation; Research and development; Silicon Valley; Silicon Valley; Singapore; Smartphones; Social entrepreneurship; Social networks; Social responsibility; Software; Southeast Asia; Startups / Start-ups; Strategic management; Strategic planning; Strategy; Taiwan; Technological innovation; Technological innovation; Technological innovation; Technology strategy; Technology transfer; Technology transfer; Telecommunications; Thailand; United States; Venture capital; Venture capital; Vietnam; Virtual customer; Web-based marketing; Wireless communication; X-teams

Andrew Lo

Andrew Lo

Charles E. and Susan T. Harris Professor

Department: Professor of Finance

Contact: (617) 253-0920, andrew.lo@mit.edu

Expertise: Analyst forecasts; Angel investing; Applied economics; Applied mathematics; Applied probability; Arbitrage pricing theory; Artificial intelligence; Asset management; Asset pricing; Banking; Banking management; Banking operations and policy; Banking regulation; Bankruptcy; Bayesian networks; Bayesian statistics; Bayesian statistics; Big data; Biopharmaceutical; Biotechnology; Bond markets; Bond negotiations; Bond pricing; Business intelligence; Business plans; Cancer; Capital budgeting; Capital controls; Capital market; CEO compensation; Clinical trials; Consumer behavior; Contagion; Corporate diversification; Corporate finance; Corporate governance; Corporate strategy and policy; Currency; Cyber security; Data acquisition; Data analysis; Data mining; Decision making; Deflation; Derivatives; Disaster recovery; Distance learning; Dividend policy; Dot-com; Drug models; eCommerce; Econometrics; Economic crisis; Economics; Education; Emerging businesses; Entrepreneurial finance; Entrepreneurial management; Equities; Euro; Exchange rates; Executive compensation; Federal Reserve; Financial econometrics; Financial engineering; Financial information technology; Financial information technology; Financial markets; Financial reporting; Financial services; Financial statement analysis; Foreign investment; Futures; Government; Healthcare; Healthcare industry; Hedge funds; Hurdle rates; Inflation; Intellectual property; Intellectual property law; Interest rates; International finance; Internet privacy issues; Intertemporal choice; Investment analysis; Investment banking; Investment risk; Investment strategies; Knowledge sharing; Macroeconomics; Mathematical programming; MBA; Medical decision making; Medicine; Mergers and acquisitions; Mobile banking; MOOCs; Mortgage funds; Mutual funds; Neural networks; New venture development; New ventures; Non-linear dynamics; Online banking; Online education; Online feedback mechanisms; Operations research; Optimal control; Optimization; Options; Patents; Pensions; Personal finance; Pharmaceuticals; Portfolio choice; Portfolio design and management; Private equity; Research and development; Retirement planning; Revenue management; Risk capital; Risk management; Sampling; Securities and Exchange Commission (SEC); Security prices; Simulation; Software agents; Startups / Start-ups; Statistics; Stochastic modeling; Stock exchange; Stock exchange consolidation; Stock market; Stock options; Stock trading; Subprime lending; Trading decisions; Treasuries; Venture capital; Wall Street; Web-based marketing

Andrey Zarur

Andrey Zarur

Department: Lecturer, Martin Trust Center for MIT Entrepreneurship

Contact: (781) 684-0239, azarur@mit.edu

Expertise: Biopharmaceutical; Biotechnology; Business plans; Climate policy; Clinical trials; Emerging businesses; Energy; Entrepreneurial management; Environment; Global climate change; Global warming; Healthcare; Innovation; Medical devices; Mexico; Multi-drug models; New ventures; Pharmaceuticals; Research and development; Startups / Start-ups; Venture capital

Using statistics can can improve clinical trials and outcomes – Dimitris Bertsimas

From Times Higher Education  Sometimes science can be personal. When my father, who was living in Greece at the time, was diagnosed with stage IV gastric cancer in 2007, I set out to find the best possible care for him. As is the case with many patients with advanced disease, drug therapy was his best course. So, after unsuccessful surgery in Greece, he came to the US for treatment. I contacted the most prestigious cancer hospitals in the country and found that they all used different drugs in different treatment regimens to treat advanced gastric cancer. As both a son and a scientist, I was surprised to discover that there was no standard treatment – something I would later realise was true of many different kinds of late-stage cancers. My family and I were therefore left without a good way to make treatment decisions. As a result, I was forced … Read More » The post Using statistics can can improve clinical trials and outcomes – Dimitris Bertsimas appeared first on MIT Sloan Experts.

Your Recent Searches

Can't find what
you're looking for?

Contact us.

Twitter

Paul Denning
Director of Media
Relations
617.253.0576
denning@mit.edu

Patricia Favreau
Associate Director of
Media Relations
617.253.3492
pfavreau@mit.edu

©2010 MIT Sloan School of Management